NMN (nicotinamide mononucleotide) is a precursor that the body converts into NAD+. NAD+ is a coenzyme essential to cellular energy production, DNA repair, and mitochondrial function, and its levels decline naturally with age.

Why would NMN affect hair growth?

Hair follicle cells are among the most energy-intensive tissues in the body, dividing rapidly throughout the growth cycle. When NMN replenishes NAD+, it activates mitochondrial ATP production and supports amino acid metabolism (leucine, isoleucine), supplying the fuel follicle cells need to stay in the active growth phase (anagen).

Is 500mg the right dose?

500mg per day was the dose used in this trial, and it produced measurable changes in hair density. However, with only 15 participants and no placebo group, this is early-stage evidence. Most NMN clinical trials use doses in the 250~500mg range.

NMN Supplementation Raised Hair Density 57% in Women in Their 40s

A clinical trial conducted by researchers at Mitsubishi Corporation Life Sciences found that 12 weeks of daily NMN supplementation produced a 57% increase in anagen hair density in women aged 40 to 50. The results, published in the journal Cosmetics (MDPI) in September 2025, are notable not just for the magnitude of change but for the metabolite evidence linking NMN directly to the biological pathway behind it.

What the Numbers Show

Fifteen healthy Japanese women aged 40 to 50 took 500mg of NMN daily for 12 weeks. Researchers tracked anagen hair density, meaning the number of actively growing hairs per square centimeter of scalp, using photographic trichogram analysis rather than self-report.

Before supplementation: 55.9 hairs/cm². After 12 weeks: 87.7 hairs/cm². That is a gain of 31.8 hairs per cm² in three months. Hair diameter also increased from 75.3μm to 78.8μm. Both numbers tell the same story: follicles that had been dormant or in a resting phase shifted back into active growth, and those that were already growing became thicker.

Participants also reported improvements in elasticity, gloss, and perceived volume on visual analog scales, alongside reduced fatigue and less perceived hair shedding.

The Mechanism Behind the Numbers

The research team went further than tracking outcomes. They analyzed blood metabolites before and after supplementation to identify which biological pathways changed.

NMN converts to NAD+ (nicotinamide adenine dinucleotide) in the body. NAD+ is a coenzyme that mitochondria, the energy-generating structures inside cells, require to produce ATP, the molecule cells use as direct fuel. NAD+ levels decline with age, with the drop becoming significant in the early 40s.

After 12 weeks of NMN, blood levels of isovalerylcarnitine, creatine, creatinine, leucine, and isoleucine all increased. Carnitine-related metabolites help shuttle fatty acids into mitochondria for energy conversion. Leucine and isoleucine are branched-chain amino acids that serve as building blocks for protein synthesis. In other words, both the energy supply pathway and the protein-building pathway showed activation simultaneously.

Hair is roughly 97% protein, primarily keratin. When follicle cells have adequate ATP and a steady supply of amino acids, they sustain the anagen phase longer. The density numbers reflect that directly.

What This Means for Women in Their 40s

Hair thinning in women typically becomes noticeable in the early to mid-40s: strands narrow, regrowth after shedding slows, and overall volume decreases. This period overlaps with declining estrogen and, separately, declining NAD+. The two processes compound each other at the follicle level.

This study is the first direct clinical signal that replenishing NAD+ precursors can produce measurable follicle-level changes in this age group. If you already take a multi-ingredient longevity or anti-aging formula, check whether NMN is included and at what dose before adding a standalone supplement. The 500mg figure here refers to NMN as a single ingredient.

Limitations Worth Noting

Fifteen participants. No placebo control group. Women only, Japanese cohort only. These constraints matter. Without a control arm, placebo effects cannot be ruled out. The sample is far too small to generalize the findings to broader populations. The study was conducted by Mitsubishi Corporation Life Sciences, which introduces a conflict-of-interest consideration that warrants transparency.

What the study does contribute is a mechanistic signal. The metabolite data provides a plausible, evidence-grounded explanation for how the outcome occurred, not just that it did. Larger randomized controlled trials would considerably strengthen the case. Until then, this sits in the category of promising early data, not established evidence.

Source: Cosmetics (MDPI)